Contrasting Nanovibronix (NASDAQ:NAOV) and Adagio Medical (NASDAQ:ADGM)

Nanovibronix (NASDAQ:NAOV) and Adagio Medical (NASDAQ:ADGM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Analyst Recommendations

This is a breakdown of recent recommendations for Nanovibronix and Adagio Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1	0	0	0	1.00
Adagio Medical	1	0	0	0	1.00

Valuation & Earnings

This table compares Nanovibronix and Adagio Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$2.34 million	2.09	-$3.70 million	($80.43)	-0.06
Adagio Medical	$600,000.00	27.07	-$75.04 million	($0.51)	-2.07

Nanovibronix has higher revenue and earnings than Adagio Medical. Adagio Medical is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Nanovibronix has a beta of 2.17, indicating that its stock price is 117% more volatile than the S&P 500. Comparatively, Adagio Medical has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500.

Profitability

This table compares Nanovibronix and Adagio Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-380.29%	-45.24%	-34.24%
Adagio Medical	N/A	-248.26%	-125.31%

Insider & Institutional Ownership

16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 48.1% of Adagio Medical shares are owned by institutional investors. 6.3% of Nanovibronix shares are owned by insiders. Comparatively, 53.5% of Adagio Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Nanovibronix beats Adagio Medical on 6 of the 11 factors compared between the two stocks.

About Nanovibronix

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.

About Adagio Medical

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company is based in Laguna Hills, California.